571 - Pembrolizumab for patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin: The phase 2 KEYNOTE-057 study
| Autor: | Boormans, J.L., Balar, A.V., De Wit, R., Kamat, A., Uchio, E., Mourey, L., Krieger, L., Singer, E.A., Bajorin, D., Grivas, P., Seo, H.K., Nishiyama, H., Konety, B., Nam, K., Kapadia, E., Frenkl, T., Kulkarini, G.S. |
|---|---|
| Zdroj: | In European Urology Supplements March 2019 18(1):e758-e759 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect